Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma

非小细胞肺癌的蛋白激酶治疗靶点

基本信息

  • 批准号:
    9766077
  • 负责人:
  • 金额:
    $ 184.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-11 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

Lung cancer is the leading cause of cancer death in the United States and world-wide, with over 85% of cases due to non-small cell lung cancer (NSCLC). The goal of our Program is to advance the pre-clinical science of NSCLC therapeutics. During the current funding period, our Program has advanced inhibitors of EGFR, promoting the pre-clinical development of osimertinib and related molecules, of TBK1, and of DDR2. In its next 5 years, our Program aims to develop compounds that will lead to more effective treatments for NSCLC and prevent or overcome resistance to existing and future targeted therapies. To accomplish these goals, the Program seeks to achieve the following overall aims via 3 inter-related and collaborative Projects and 4 intellectually driven Shared Resource Cores. --Overall Aim 1. Develop inhibitors and/or degraders focused on mutant EGFR, KRAS signaling effectors, and mechanisms of transcriptional adaptation in non-small cell lung cancer. --Overall Aim 2. Characterize these compounds and their targets pharmacologically using genetically defined cellular and animal models of lung cancer. --Overall Aim 3. Develop and assess combinations of these potent and selective novel agents with existing therapies to prevent and overcome therapeutic resistance. These aims leverage innovations in chemistry and structural biology—the development of allosteric kinase inhibitors and selective degraders—coupled with expertise in lung cancer biology, lung cancer cellular and animal modeling, and functional genomic approaches to understanding pathways, through the Projects and Cores. The broad aims will be implemented with three focused projects aimed at developing inhibitors of key pathways in NSCLC as well as over-arching mechanisms of resistance: --Project 1: Development of pharmacologic strategies to degrade mutant EGFR. --Project 2: Identification of combination therapy for KRAS-driven lung cancers. --Project 3: Targeting transcriptional mechanisms of therapeutic resistance in non-small cell lung cancer. Each Project and the overall Program is based on the innovative, technology-driven Cores, each led by faculty with expertise in the specific areas. Core A: Medicinal Chemistry. Core B: Structure and Biochemistry. Core C: Animal Modeling and Preclinical Therapeutics. Core D: Program Administration. The integration of the three Projects and the four Cores will enable an effective co-ordination to meet Program aims by cross-fertilization of lung cancer focus and technological expertise.
肺癌是美国和世界范围内癌症死亡的主要原因,超过85%的人死于肺癌

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATTHEW L. MEYERSON其他文献

MATTHEW L. MEYERSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATTHEW L. MEYERSON', 18)}}的其他基金

Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
肺腺癌:从基因组改变到治疗发现
  • 批准号:
    10299281
  • 财政年份:
    2015
  • 资助金额:
    $ 184.71万
  • 项目类别:
How do genome alterations cause human lung cancer?
基因组改变如何导致人类肺癌?
  • 批准号:
    8955791
  • 财政年份:
    2015
  • 资助金额:
    $ 184.71万
  • 项目类别:
NKX2-1 Enhancer Amplification and Lineage Addiction in Lung Adenocarcinoma
肺腺癌中的 NKX2-1 增强子扩增和谱系成瘾
  • 批准号:
    10598959
  • 财政年份:
    2015
  • 资助金额:
    $ 184.71万
  • 项目类别:
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
肺腺癌:从基因组改变到治疗发现
  • 批准号:
    10455040
  • 财政年份:
    2015
  • 资助金额:
    $ 184.71万
  • 项目类别:
How do genome alterations cause human lung cancer?
基因组改变如何导致人类肺癌?
  • 批准号:
    9118129
  • 财政年份:
    2015
  • 资助金额:
    $ 184.71万
  • 项目类别:
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
肺腺癌:从基因组改变到治疗发现
  • 批准号:
    10683176
  • 财政年份:
    2015
  • 资助金额:
    $ 184.71万
  • 项目类别:
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
非小细胞肺癌的蛋白激酶治疗靶点
  • 批准号:
    8490596
  • 财政年份:
    2012
  • 资助金额:
    $ 184.71万
  • 项目类别:
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
非小细胞肺癌的蛋白激酶治疗靶点
  • 批准号:
    8660037
  • 财政年份:
    2012
  • 资助金额:
    $ 184.71万
  • 项目类别:
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
非小细胞肺癌的蛋白激酶治疗靶点
  • 批准号:
    8844212
  • 财政年份:
    2012
  • 资助金额:
    $ 184.71万
  • 项目类别:
Project 3: Targeting transcriptional mechanisms of therapeutic resistance in non-small cell lung cancer.
项目 3:针对非小细胞肺癌治疗耐药的转录机制。
  • 批准号:
    10231100
  • 财政年份:
    2012
  • 资助金额:
    $ 184.71万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 184.71万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 184.71万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 184.71万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 184.71万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 184.71万
  • 项目类别:
    Continuing Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 184.71万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 184.71万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Analysis of thermoregulatory mechanisms by the CNS using model animals of female-dominant infectious hypothermia
使用雌性传染性低体温模型动物分析中枢神经系统的体温调节机制
  • 批准号:
    23KK0126
  • 财政年份:
    2023
  • 资助金额:
    $ 184.71万
  • 项目类别:
    Fund for the Promotion of Joint International Research (International Collaborative Research)
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 184.71万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 184.71万
  • 项目类别:
    Training Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了